President Donald Trump announced on Saturday that all 50 states have agreed to join a Medicaid drug pricing model, a sweeping expansion that the administration says will reduce prescription drug costs for millions of Americans enrolled in government health programs. The announcement was made as Trump returned from Camp David.

The Medicaid drug pricing model ties reimbursement rates for certain medications to the lower prices that Medicaid programs typically negotiate compared to other payers. By bringing all states into the program, the administration aims to leverage the full combined purchasing power of state Medicaid programs to drive down costs more broadly.

Medicaid currently covers more than 80 million low-income Americans, and drug spending within the program has long been a point of policy debate. States have historically had varying levels of engagement with federal drug pricing demonstration programs, making unanimous participation notable.

The White House framed the development as a major win for its drug pricing agenda, which has also included executive orders targeting international reference pricing and most-favored-nation pricing frameworks. Details on the specific drugs covered under the expanded model and the timeline for implementation were not immediately available following the announcement.

The news arrives amid broader economic pressures on American businesses and consumers, with companies continuing to navigate elevated interest rates, fuel costs, and tariff-related expenses. Healthcare affordability has remained a central concern for voters across the political spectrum heading into the coming election cycle.